Where Keros Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Keros Therapeutics (NASDAQ:KROS) has received positive analyst ratings in the last quarter, with 3 bullish and 1 somewhat bullish ratings. The average 12-month price target for the company is $93.75, a decrease of 21.88% from the previous average of $120.00.
July 26, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Keros Therapeutics has received positive analyst ratings, but the average 12-month price target has decreased.
While the company has received positive ratings from analysts, the decrease in the average 12-month price target could indicate a potential decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100